title: Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study.
abstract: OBJECTIVE
  The aim of this study was to examine the visual outcome of patients receiving an intravitreal injection of triamcinolone acetonide (TA) as treatment of diffuse diabetic macular edema (DDME).
  
  
  METHODS
  This prospective, placebo-controlled, randomized, clinical interventional study included 40 eyes (38 patients) with DDME, with 28 (70%) eyes randomized to treatment and 12 (30%) eyes randomized to receive a placebo injection. Thirty-six (36) (90%) eyes completed the 3-month study visit, and 32 (80%) eyes completed the 6-month study visit. The treatment group received an intravitreal injection of approximately 20 mg of TA.
  
  
  RESULTS
  Visual acuity increased significantly (P < 0.001) in the study group by 3.4 +/- 2.5 Snellen lines. In the control group, visual acuity did not change significantly (P = 0.07) during follow-up. Difference in change of best visual acuity was significant (P < 0.001) between both groups. At 3 months after baseline, 11 (11/26; 42%) eyes and 10 (10/26; 39%) eyes, respectively, improved by at least 2 and 3 lines, respectively, in the study group, versus 2 (2/10; 20%) eyes and 1 (1/10; 10%) eye in the control group. At 6 months after baseline, 11 (11/23; 48%) eyes and 9 (9/23; 39%) eyes, respectively, improved by at least 2 and 3 lines, respectively, in the study group, versus 0 (0%) eyes and 0 (0%) eyes in the control group. The difference was significant for the 2-line improvement (P = 0.01) and 3-line improvement (P = 0.03).
  
  
  CONCLUSIONS
  Using a dosage of approximately 20 mg of intravitreal TA, visual acuity temporarily increases for 6 months after injection.
authors.affiliation: Department of Ophthalmology, Faculty of Clinical Medicine Mannheim of the Ruprecht-Karls-University of Heidelberg, Germany. Jost.Jonas@augen.ma.uni-heidelberg.de
authors.forename: Jost B
authors.initials: JB
authors.lastname: Jonas
authors.forename: Bernd A
authors.initials: BA
authors.lastname: Kamppeter
authors.forename: Bjoern
authors.initials: B
authors.lastname: Harder
authors.forename: Urs
authors.initials: U
authors.lastname: Vossmerbaeumer
authors.forename: Gangolf
authors.initials: G
authors.lastname: Sauder
authors.forename: Ulrich H M
authors.initials: UH
authors.lastname: Spandau
mesh_terms: D000368:Aged; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body / Q000187:drug effects*
chemical_list: D014222:Triamcinolone Acetonide